Veracyte

VCYT

Market cap $3.36B

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025. Preliminary Unaudited Financial Results For the fourth quarter ended December 31, 2025, as compared to the same period of 2024, Veracyte expects to report: Total revenue of between $138 million and $140 million, an increase of between 16% and 18% Testing revenue of.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 9:45 a.m. Pacific Time. Live audio webcasts of the company's presentations will be available by visiting Veracyte's website at http://investor.veracyte.com/events-presentations. A replay of the webcast will be available for 30 days following the conclu.

VCYT, IDXX and ISRG ride on genAI-powered growth as medical instruments evolve, even with weak industry returns and cost pressures.

VCYT's Afirma and Decipher fuel strong test volume growth and a debt-free balance sheet, but rising macro costs and expenses temper the outlook.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Veracyte surges 27.5% after Q3 earnings and revenues beat estimates, driven by strong Decipher and Afirma test growth.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Wolfe Research Healthcare Conference – New York, NY Fireside Chat on November 17th at 10:00 a.m. Eastern Time Jefferies Global Healthcare Conference – London, UK Fireside Chat on November 20th at 11:30 a.m. Greenwich Mean Time Stephens Annual Investment Conference – Nashville, TN Fireside Chat on November 20t.

Veracyte, Inc. ( VCYT ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Shayla Gorman - Director of Investor Relations Marc Stapley - CEO & Director Rebecca Chambers - Executive VP & CFO John Leite - Global Chief Commercial Officer Phillip Febbo - Chief Scientific & Medical Officer Conference Call Participants Douglas Schenkel - Wolfe Research, LLC Puneet Souda - Leerink Partners LLC, Research Division Kyle Mikson - Canaccord Genuity Corp., Research Division Lu Li - UBS Investment Bank, Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Benjamin Mee - Stephens Inc., Research Division Andrew Brackmann - William Blair & Company L.L.C., Research Division Andrew Cooper - Raymond James & Associates, Inc., Research Division Presentation Operator Good day, and thank you for standing by.

Veracyte (VCYT) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.19 per share a year ago.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2025. “We delivered another outstanding quarter of testing revenue growth and adjusted EBITDA margin expansion, enabling us to raise both our revenue and profitability guidance,” said Marc Stapley, Veracyte's chief executive officer. “We continue to advance our mission of transforming cancer care by generat.